Clinical outcomes in patients in any phase of CML treated with ponatinib in France—Data from the TOPASE observational study
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19819 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift British Journal of Haematology, 2024. Verfasst von F Huguet und 22 weiteren Autor:innen. Beteiligte Einrichtung: Haematology Department, Cancer University Institute, University Hospital, Toulouse, France. Hauptthemen laut MEDLINE: Imidazoles, Pyridazines, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Incyte Biosciences France.
Abstract (Originalsprache)
The TOPASE study was set up to evaluate the outcomes of chronic myeloid leukaemia [CML] patients treated with ponatinib (PON) in a real‐world setting in France. One hundred and twenty CML patients, 105 in chronic phase (CP), 8 in accelerated phase (AP) and 7 in blastic phase (BP) were included. Fifty‐one (49%) of the CP‐CML patients were in third line of treatment. The trigger for PON initiation in CP‐CML was ‘poor response’ in 67 patients, ‘poor tolerance’ in 28 patients and ‘response enhancement’ in seven patients. The median dose at initiation was 30 mg/day [Q1; Q3 = 15; 30] in CP‐CML and 45 mg/day [Q1; Q3 = 30; 45] in AP/BP‐CML. Of 98 CP‐CML evaluable patients, 72 (73.5%) were considered as responders (MMR) at one time point at least once, especially for those in second line of treatment and/or presenting a T315I mutation. Ninety‐six of 120 (80%) patients reported at least one adverse event. An arterial occlusive event (AOE) was reported in 11 patients (9.2%). Thus, these real‐life data confirm the potency of ponatinib in resistant or intolerant patients with an acceptable safety profile in non‐selected patients. NCT number : NCT04048564.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Haematology Department, Cancer University Institute, University Hospital, Toulouse, France.
- Fi LMC Centre Léon Bérard, Lyon, France.
- Haematology Department, Regional University Hospital Brabois, Vandoeuvre-les-Nancy, France.
- Haematoloy and Cellular Therapy Department, University Hospital, Poitiers, France.
- CIC INSERM 1402, Poitiers, France.
- Hospital Centre, Avignon, France.
ORCID-Profile: E Cayssials, L Roy, M Berger, G Etienne, F E Nicolini
Förderung
- Incyte Biosciences France
Zitieren
APA
Huguet, F., Guerci-Bresler, A., Roth-Guepin, G., Cayssials, E., Slama, B., Santagostino, A., Penot, A., Quittet, P., Cony-Makhoul, P., Saad, A., Bastie, J. N., Hacini, M., Coiteux, V., Uzunov, M., Roy, L., Le Clech, L., Berger, M., Agneray, A. M., Messas, E., …, & Rousselot, P. (2024). Clinical outcomes in patients in any phase of CML treated with ponatinib in France—Data from the TOPASE observational study. British Journal of Haematology. https://doi.org/10.1111/bjh.19819
Vancouver
Huguet F, Guerci-Bresler A, Roth-Guepin G, Cayssials E, Slama B, Santagostino A, et al. Clinical outcomes in patients in any phase of CML treated with ponatinib in France—Data from the TOPASE observational study. British Journal of Haematology. 2024. doi:10.1111/bjh.19819
BibTeX
@article{Huguet2024,
author = {Huguet, F and Guerci-Bresler, A and Roth-Guepin, G and Cayssials, E and Slama, B and Santagostino, A and Penot, A and Quittet, P and Cony-Makhoul, P and Saad, A and Bastie, J N and Hacini, M and Coiteux, V and Uzunov, M and Roy, L and Le Clech, L and Berger, M and Agneray, A M and Messas, E and Etienne, G and Turhan, A and Nicolini, F E and Rousselot, P},
title = {Clinical outcomes in patients in any phase of CML treated with ponatinib in France—Data from the TOPASE observational study},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19819}
}
EUVIMED